Biopharmaceutical major Biocon said on Thursday said its insulin facility in Malaysia has been approved by the European Medicines Agency.
Biocon Sdn Bhd, which operates Asias largest integrated insulin facility, has received the Certificate of Good Manufacturing Practices. The site was inspected in May.
"This approval expands Biocons capacities multi-fold with the new large-scale devices facility coming up to speed to serve the growing needs of people with
